Lupin Ltd
₹2328.70
(0.11%)
Sat, 25 Apr 2026, 11:03 am
Health Technology
Pharmaceuticals: Other
24.5KLupin Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 24.18 | 16.10 | 9.92 | 11.44 | 20.88 | 21.58 | 27.36 | 21.50 | 22.94 | 37.73 | 29.65 | 25.59 | 132.92 | 55.34 | 0 | 38.20 | 0 | 68.83 | 38.64 | 28.27 |
| Price to book ratio | 6.56 | 5.57 | 3.17 | 4.01 | 5.63 | 5.65 | 5.90 | 5.41 | 6.05 | 10.17 | 5.98 | 4.83 | 2.45 | 2.43 | 2.13 | 3.36 | 2.80 | 2.37 | 5.17 | 5.39 |
| Price to sales ratio | 2.42 | 2.43 | 1.50 | 1.52 | 3 | 3.26 | 3.41 | 2.99 | 3.80 | 7.20 | 4.86 | 3.85 | 2.15 | 2.33 | 1.76 | 3.09 | 2.08 | 1.80 | 3.76 | 4.17 |
| Price to cash flow ratio | 39.41 | 30.27 | 17.01 | 13.54 | 22.28 | 24.24 | 44.83 | 23.15 | 21.17 | 32.44 | 0 | 16.32 | 20.99 | 22.53 | 21.25 | 26.87 | 122.67 | 17.38 | 21.68 | 31.99 |
| Enterprise value | 45.55B | 53.68B | 49.89B | 69B | 151.95B | 194.03B | 250.43B | 290.17B | 418.52B | 890.43B | 730.82B | 705.78B | 389.15B | 390.1B | 285.74B | 475.42B | 361.8B | 324.9B | 749.28B | 941.05B |
| Enterprise value to EBITDA ratio | 19.58 | 17.75 | 10.63 | 6.34 | 17.12 | 17.91 | 18.24 | 13.36 | 14.37 | 24.78 | 19.50 | 16.54 | 6.54 | 16.57 | 13.06 | 18.52 | 17.19 | 19.42 | 21.11 | 19.31 |
| Debt to equity ratio | 1.49 | 0.99 | 0.94 | 0.86 | 0.44 | 0.35 | 0.41 | 0.22 | 0.09 | 0.06 | 0.64 | 0.59 | 0.53 | 0.62 | 0.53 | 0.37 | 0.34 | 0.37 | 0.20 | 0.32 |
| Return on equity % | 30.47 | 40.55 | 37.92 | 37.09 | 34.14 | 29.50 | 23.80 | 28.52 | 30.27 | 30.41 | 22.57 | 20.74 | 1.86 | 3.75 | -3.04 | 9.24 | -11.79 | 3.50 | 14.34 | 20.88 |
Lupin Ltd Enterprise Value
The Lupin Ltd Enterprise Value is a key financial metric used by investors to evaluate Lupin Ltd's valuation, profitability, and overall financial performance. Tracking the Lupin Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lupin Ltd (NSE: LUPIN, BSE: 500257) is currently trading at ₹2328.70, with a market capitalization of ₹1062.6B. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Lupin Ltd Enterprise Value is essential for fundamental analysis.
Lupin Ltd Enterprise Value Current Value
The current Lupin Ltd Enterprise Value stands at 941.05B.
The latest Lupin Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Lupin Ltd Enterprise Value Historical Trend
The Lupin Ltd Enterprise Value has shown the following historical trend:
- 2024: 941.05B
- 2023: 749.28B
- 2022: 324.9B
- 2021: 361.8B
- 2020: 475.42B
The recent rise in Lupin Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Lupin Ltd Enterprise Value Indicates for Investors
The Lupin Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Lupin Ltd.
Lupin Ltd Enterprise Value Analysis Summary
The Lupin Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lupin Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lupin Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800